393 related articles for article (PubMed ID: 12776001)
21. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
[TBL] [Abstract][Full Text] [Related]
22. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
Tonini M; Pace F
Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
[TBL] [Abstract][Full Text] [Related]
23. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
Bellini M; Rappelli L; Blandizzi C; Costa F; Stasi C; Colucci R; Giannaccini G; Marazziti D; Betti L; Baroni S; Mumolo MG; Marchi S; Del Tacca M
Am J Gastroenterol; 2003 Dec; 98(12):2705-11. PubMed ID: 14687821
[TBL] [Abstract][Full Text] [Related]
24. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
[TBL] [Abstract][Full Text] [Related]
25. Serotoninergic neuroenteric modulators.
Talley NJ
Lancet; 2001 Dec; 358(9298):2061-8. PubMed ID: 11755632
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
[TBL] [Abstract][Full Text] [Related]
27. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel.
Gershon MD
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():15-30. PubMed ID: 10429737
[TBL] [Abstract][Full Text] [Related]
28. The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.
Nakai A; Diksic M; Kumakura Y; D'Souza D; Kersey K
Neurogastroenterol Motil; 2005 Apr; 17(2):212-21. PubMed ID: 15787942
[TBL] [Abstract][Full Text] [Related]
29. [Irritable bowel syndrome as an interdisciplinary clinical challenge. Current views on its pathophysiology, diagnosis and treatment].
Hollerbach S; Elsenbruch S; Enck P
Dtsch Med Wochenschr; 2001 Apr; 126(16):472-8. PubMed ID: 11360454
[No Abstract] [Full Text] [Related]
30. Peripherally acting therapies for the treatment of irritable bowel syndrome.
Saad RJ
Gastroenterol Clin North Am; 2011 Mar; 40(1):163-82. PubMed ID: 21333906
[TBL] [Abstract][Full Text] [Related]
31. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
Gershon MD
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
Schoenfeld P
Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
[TBL] [Abstract][Full Text] [Related]
33. New drugs to treat irritable bowel syndrome being tested.
Mayo Clin Health Lett; 2000 Mar; 18(3):4. PubMed ID: 10734837
[No Abstract] [Full Text] [Related]
34. Pharmacologic therapy for the irritable bowel syndrome.
Talley NJ
Am J Gastroenterol; 2003 Apr; 98(4):750-8. PubMed ID: 12738451
[TBL] [Abstract][Full Text] [Related]
35. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
[No Abstract] [Full Text] [Related]
36. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
Miller DP; Alfredson T; Cook SF; Sands BE; Walker AM
Am J Gastroenterol; 2003 May; 98(5):1117-22. PubMed ID: 12809837
[TBL] [Abstract][Full Text] [Related]
37. [Tegaserod in treatment of women with irritable bowel syndrome].
Munck LK; Ainsworth MA
Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
[TBL] [Abstract][Full Text] [Related]
38. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Lewis JH
Drug Saf; 2011 Jul; 34(7):545-65. PubMed ID: 21663331
[TBL] [Abstract][Full Text] [Related]
39. The role of serotonin in the pathophysiology of irritable bowel syndrome.
Crowell MD
Am J Manag Care; 2001 Jul; 7(8 Suppl):S252-60. PubMed ID: 11474910
[TBL] [Abstract][Full Text] [Related]
40. New developments in the treatment of irritable bowel syndrome.
De Schryver AM; Samsom M
Scand J Gastroenterol Suppl; 2000; (232):38-42. PubMed ID: 11232489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
